Coagulation factor XIII A chain Antibody [F13A1/1683] | 33-844

Coagulation factor XIII A chain Antibody [F13A1/1683] | 33-844 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: A human partial recombinant protein corresponding to amino acids 46-181 was used as the immunogen for the Factor XIIIa antibody.

Research Area: Cancer

Tested Application: WB, E, Flow, IF, IHC-P

Application: ELISA: order the BSA-free formulation for coating
Immunofluorescence: 1-2 ug/ml
Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunohistochemistry (FFPE) : 1-2 ug/ml for 30 min at RT
Prediluted IHC only format: incubate for 30 min at RT (1)
Titering of the Factor XIIIa antibody may be required for optimal performance.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required) , drip mAb solution onto the tissue section and incubate at RT for 30 min.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: F13A1/1683

Isotype: IgG2b, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: F13A1, coagulation factor XIII, A1 polypeptide, RP11-232H4.1, F13A, Coagulation factor XIII A chain, Coagulation factor XIII, A polypeptide, TGase, bA525O21.1 (coagulation factor XIII, A1 polypeptide) , coagulation factor XIII A1 subunit, factor XIIIa

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: Factor XIIIa has been identified in platelets, megakaryocytes, and fibroblast-like mesenchymal or histiocytic cells in the placenta, uterus, and prostate, monocytes and macrophages and dermal dendritic cells. Anti-Factor XIIIa has been found to be useful in differentiating between dermatofibroma (almost all cases are positive) , dermatofibrosarcoma protuberans (-/+) and desmoplastic malignant melanoma (-) . Anti-Factor XIIIa positivity is also seen in capillary hemagioblastoma, hemangioendothelioma, hemangiopericytoma, xanthogranuloma, xanthoma, hepatocellular carcinoma, glomus tumor, and meningioma.